Neurofibroma, Plexiform clinical trials

The registry lists 63 studies for Neurofibroma, Plexiform across more than 10 countries. 19 are recruiting or about to start. 19 of them are mainly about Neurofibroma, Plexiform (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Neurofibroma, Plexiform studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 20
Recruiting: 13
Active, not recruiting: 13
Terminated: 6
Withdrawn: 4
Not yet recruiting: 3

Phase

Phase 2: 28
Phase 1: 13
Phase 3: 4
Phase 4: 1
Early Phase 1: 1

Where

United States: 43
China: 10
Canada: 5
France: 5
Germany: 5
United Kingdom: 4

Who runs them

National Cancer Institute (NCI) (18) · AstraZeneca (6) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (3) · Indiana University (3) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (3) · Novartis Pharmaceuticals (3) · University of Alabama at Birmingham (3) · Children's Hospital of Philadelphia (2)

What is being tested here

Drugs under test in Neurofibroma, Plexiform studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
AZD 6244	3	1	10
Luvometinib	1	1	3
Cabozantinib	1	0	2
Pexidartinib	1	0	1
Tunlametinib	1	0	1
Trametinib	0	0	4
Pirfenidone	0	0	3
Everolimus	0	0	2
Imatinib	0	0	2
Mirdametinib	0	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open

Coming up

3phase 3 studies under way

9studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9

Nov 2026Pediatric Long-Term Follow-up and Rollover Study · Novartis Pharmaceuticals
Dec 2026Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... · National Cancer Institute (NCI)
Jan 2027AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors · National Cancer Institute (NCI)
Mar 2027Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. · St. Justine's Hospital
May 2027A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1) · National Cancer Institute (NCI)
Jun 2027Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 · Ann & Robert H Lurie Children's Hospital of Chicago
Jun 2027A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 · Healx Limited
Jun 2027Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs · AstraZeneca
Jun 2027Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) · National Cancer Institute (NCI)

Who these studies take

Of the 13 Neurofibroma, Plexiform studies recruiting now, 7 (54%) set no upper age limit and 2 (15%) stop at 75 or younger. 9 (69%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (8%) take healthy volunteers.

Recruiting studies that take each age, of 13
Age	Women	Men
10	6 (46%)	6 (46%)
18	12 (92%)	12 (92%)
30	12 (92%)	12 (92%)
40	11 (85%)	11 (85%)
50	11 (85%)	11 (85%)
65	11 (85%)	11 (85%)
75	11 (85%)	11 (85%)
85	10 (77%)	10 (77%)

Across all 63 studies, recruiting or not: 51% stop at 75 or younger and 46% at 65; 79% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 63. Browse all 63 → or search them.